Transforming the Treatment of Neuromuscular Diseases

Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.

Creating the new generation of genetic therapies

Advancing revolutionary therapies to treat degenerative neuromuscular diseases

Careers at PepGen

We’re seeking passionate individuals who can help us to create therapies to improve the future of people living with neuromuscular diseases

Latest Updates

PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

Initiation of Phase 1 Study Marks PepGen’s Transition to a Clinical Stage Company    This …

Read More →

PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development

Dr. Mellion brings deep experience in neuromuscular disease research and treatment as a biopharma executive, …

Read More →

PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology

BOSTON, March 30, 2022 – PepGen, Inc., advancing the next generation of oligonucleotide therapies with …

Read More →